Stada Strikes Deals With Lobsor And MediPharm
Lobsor Offers Value-Added Parkinson's Disease Treatment; MediPharm Adds Cannabis
Stada's Britannia Pharmaceuticals has acquired Sweden's Lobsor and its Lecigon gel formulation which is already approved in the Nordics and combines levodopa, carbidopa and entacapone infused via a lightweight pump. Meanwhile, Stada has also formed an alliance with MediPharm Labs for medical cannabis.
You may also be interested in...
Also, deals between Boehringer Ingelheim/Oxford BioTherapeutics, Bausch/Eyenovia, Ligand/HitGen, Moderna/Merck & Co., Vincera/Bayer, Genentech/Kineta, Selecta/IGAN, RedHill/AstraZeneca, Urovant/Sunovion, Biogen/Scribe, BridgeBio/Eidos, Elevar/Taiba
A long-term, patient-centric group of investors is backing SparingVision's bid to develop a gene therapy treatment for retinitis pigmentosa that could be effective regardless of mutation.
Palforzia will almost certainly be the first treatment to get the green light for peanut allergy in Europe and its new owner will be hoping for a more successful launch than has been seen in the US.